<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2000">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135130</url>
  </required_header>
  <id_info>
    <org_study_id>ON101CLOS01</org_study_id>
    <nct_id>NCT05135130</nct_id>
  </id_info>
  <brief_title>Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer</brief_title>
  <official_title>A Retrospective Record-review Study in Patients Who Had Participated in the ON101CLCT02 Diabetic Foot Ulcer Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oneness Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oneness Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the medical cost of illness for DFUs on the patients&#xD;
      who had used ON101 or Aquacel® in the ON101CLCT02 trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 4, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demographic characteristics</measure>
    <time_frame>Up to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound characteristics of DFUs (classification and proportion)</measure>
    <time_frame>Up to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of DFU recurrence after completing or withdrawing from the ON101CLCT02 trial</measure>
    <time_frame>Up to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical costs due to DFUs</measure>
    <time_frame>Up to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of wound infection, gangrene, and amputation</measure>
    <time_frame>Up to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of wound infection, gangrene, and amputation</measure>
    <time_frame>Up to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>ON101 Cream</arm_group_label>
    <description>Patients Who Had Participated in the ON101CLCT02 Diabetic Foot Ulcer Trial and assigned to ON101 Cream arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aquacel® Hydrofiber® dressing</arm_group_label>
    <description>Patients Who Had Participated in the ON101CLCT02 Diabetic Foot Ulcer Trial and assigned to Aquacel® Hydrofiber® dressing arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ON101 Cream</intervention_name>
    <description>Not applicable in this retrospective study</description>
    <arm_group_label>ON101 Cream</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The ON101CLCT02 trial enrolled 236 subjects and was conducted in Taiwan, China, and USA.&#xD;
        The target population of this study consists of the Taiwanese DFU patients who had&#xD;
        completed or early withdrawn from the ON101CLCT02 trial.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        No additional inclusion or exclusion criteria will be applied.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyi-Gen Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oneness Biotech Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

